INTERFERON THERAPY OF CRYPTOGENIC CHRONIC ACTIVE LIVER-DISEASE AND ITS RELATIONSHIP TO ANTI-HCV

被引：0
作者：
DIODATI, G
BONETTI, P
TAGGER, A
ALBERTI, A
REALDI, G
RUOL, A
机构：
[1] UNIV MILAN,INST VIROL,I-20122 MILAN,ITALY
[2] UNIV SASSARI,MED GEN CLIN,I-07100 SASSARI,ITALY
来源：
ARCHIVES OF VIROLOGY | 1992年
关键词：
D O I：
暂无
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
In a randomized controlled trial of Interferon (IFN) in 60 patients (30 treated and 30 controls) with cryptogenic chronic active liver disease, 70% of treated patients showed complete response, but a high rate of biochemical relapse (62%) was noted. In these cases, a second response to higher doses of IFN has been more difficult and less frequent. A response to IFN was found in 88.5% of anti-HCV positive treated patients and only in 25% of anti-HCV negative. We suggest that serum anti-HCV is a suitable test to predict the response to IFN.
引用
收藏
页码：299 / 303
页数：5
相关论文
共 50 条
[41]   Regression of fibrosis in interferon-free sofosbuvir-based anti-HCV therapy after liver transplantation [J].
Seifert, Leon L. ;
Vorona, Elena ;
Schmidt, Hartmut H. .
HEPATOLOGY, 2014, 60 (06) :1277A-1277A
[42]   RESPONSES TO CORTICOSTEROID-THERAPY IN CHRONIC ACTIVE LIVER-DISEASE - EFFECT OF HEPATITIS-C VIRUS (HCV) INFECTION [J].
THIELE, DL ;
DUCHARME, L ;
MIMMS, L ;
CUTHBERT, JA ;
LEE, WM ;
COMBES, B .
HEPATOLOGY, 1991, 14 (04) :A61-A61
[43]   CURRENT THERAPY OF CHRONIC LIVER-DISEASE [J].
STAVINOHA, MW ;
SOLOWAY, RD .
DRUGS, 1990, 39 (06) :814-840
[44]   EVALUATION OF LIVER FIBROSIS IN PATIENTS WITH CRYPTOGENIC CHRONIC LIVER-DISEASE AND ITS POSSIBLE CLINICAL AND PROGNOSTIC-SIGNIFICANCE [J].
DIODATI, G ;
BONETTI, P ;
PLEBANI, M ;
NOVENTA, F ;
REALDI, G .
JOURNAL OF HEPATOLOGY, 1987, 5 :S121-S121
[45]   IMMUNOSUPPRESSIVE THERAPY IN CHRONIC LIVER-DISEASE [J].
SHERLOCK, S .
MINERVA MEDICA, 1978, 69 (38) :2605-2609
[46]   ANTIBODY TO HEPATITIS-C VIRUS IN CRYPTOGENIC CHRONIC LIVER-DISEASE [J].
DIODATI, G ;
TAGGER, A ;
BONETTI, P ;
RIBERO, ML ;
DRAGO, C ;
CAVALLETTO, D ;
GROSSI, A ;
REALDI, G ;
RUOL, A ;
ALBERTI, A .
JOURNAL OF MEDICAL VIROLOGY, 1991, 35 (03) :151-154
[47]   CONFIRMATION OF ANTI-HCV EIA REACTIVITIES BY RIBA AND NEUTRALIZATION ASSAY AMONG BLOOD-DONORS AND PATIENTS WITH CHRONIC LIVER-DISEASE AND HEPATOCELLULAR-CARCINOMA [J].
TANZI, E ;
GALLI, C ;
DELAITO, M ;
BERTIN, T ;
PIZZOCOLO, G ;
RODELLA, A ;
BUSCARINI, L ;
SBOLLI, G ;
ROSSI, U ;
ROMANO, L ;
CHIARAMONTE, M ;
ZANETTI, AR .
ARCHIVES OF VIROLOGY, 1992, :227-231
[48]   CIRCULATING THYROXINE IN CHRONIC ACTIVE LIVER-DISEASE [J].
BARZILAI, DC ;
SOLOWAY, RD ;
SUMMERSKILL, WH ;
SCHOENFIELD, LJ .
ISRAEL JOURNAL OF MEDICAL SCIENCES, 1974, 10 (11) :1405-1409
[49]   Prognostic markers of liver disease progression in anti-HCV positive hemophiliacs [J].
Tradati, F ;
Gringeri, A ;
Dragoni, F ;
Cafolla, A ;
Arcieri, R ;
Mannucci, PM .
THROMBOSIS AND HAEMOSTASIS, 1997, :P1854-P1854
[50]   ANTISALMONELLA AGGLUTININS IN CHRONIC ACTIVE LIVER-DISEASE [J].
BIANCHI, PA ;
ATTILI, L ;
RANZI, T ;
PORRO, GB .
ARCHIVES FRANCAISES DES MALADIES DE L APPAREIL DIGESTIF, 1972, 61 (6-7) :C334-&
12345